```html

Jaundice due to Hepatitis – A Comprehensive Medical Guide

Overview

Jaundice is a yellow discoloration of the skin, sclerae (the whites of the eyes), and mucous membranes caused by an accumulation of bilirubin in the bloodstream. When jaundice accompanies hepatitis—a viral, autoimmune, or toxic inflammation of the liver—it signals that the liver’s ability to process and excrete bilirubin is compromised.

Who it affects: Anyone infected with hepatitis can develop jaundice, but it is most common in:

• Adults ages 20‑50, the peak incidence for hepatitis B and C infection.
• Infants born to mothers with hepatitis B or C (vertical transmission).
• People with underlying liver disease (e.g., alcoholic liver disease, non‑alcoholic fatty liver disease).

Prevalence: According to the World Health Organization, an estimated 296 million people worldwide live with chronic hepatitis B and 58 million with chronic hepatitis C. About 25‑30 % of those with acute hepatitis develop clinically apparent jaundice, while the proportion rises to 50‑70 % in chronic hepatitis when liver function deteriorates.<sup>1,2</sup>

Symptoms

Jaundice is just one manifestation of liver dysfunction. The full symptom spectrum varies with the type of hepatitis (A, B, C, D, E) and the stage (acute vs. chronic).

General symptoms of jaundice

• Yellow skin and eyes: The most recognizable sign; begins on the face and spreads down the torso.
• Dark urine: Bilirubin excreted by the kidneys darkens urine to amber or brown.
• Pale or clay‑colored stools: Lack of bilirubin reaching the intestines.
• Itching (pruritus): Bile salts deposited in the skin.
• Fatigue & weakness: Poor liver energy metabolism.

Additional hepatitis‑related symptoms

• Fever, chills, and flu‑like malaise (common in acute hepatitis A/E).
• Upper right‑abdominal pain or tenderness (liver capsule stretch).
• Loss of appetite, nausea, vomiting.
• Unintended weight loss.
• Joint or muscle aches (particularly with hepatitis B).
• Swelling of the abdomen (ascites) in advanced disease.
• Easy bruising or bleeding (due to decreased clotting factors).
• Confusion, forgetfulness, or “hepatic encephalopathy” in severe liver failure.

Causes and Risk Factors

Jaundice can result from any type of hepatitis that impairs bilirubin metabolism. The root causes differ by hepatitis type.

Viral hepatitis

• Hepatitis A (HAV): Fecal‑oral transmission; contaminated food or water.
• Hepatitis B (HBV): Blood‑borne; sexual contact, sharing needles, perinatal transmission.
• Hepatitis C (HCV): Primarily blood exposure; needle sharing, unsafe medical injections.
• Hepatitis D (HDV): Requires HBV co‑infection; same routes as HBV.
• Hepatitis E (HEV): Fecal‑oral; common in developing regions with poor sanitation.

Non‑viral causes

• Autoimmune hepatitis: The body attacks liver cells; more common in women.
• Alcoholic hepatitis: Chronic heavy alcohol use damages hepatocytes.
• Drug‑induced hepatitis: Acetaminophen overdose, certain antibiotics, anti‑seizure meds.
• Metabolic diseases: Wilson’s disease (copper overload), hemochromatosis (iron overload).

Key risk factors

• Unprotected sex or multiple partners.
• Injection‑drug use or sharing of personal grooming items (razors, toothbrushes).
• Travel to endemic regions without proper vaccination (HAV, HEV, HBV).
• Chronic alcohol consumption (> 3 drinks/day for men, > 2 for women).
• Underlying chronic liver disease (NAFLD, hepatitis B/C co‑infection).
• Family history of autoimmune liver disease.

Diagnosis

Diagnosing jaundice due to hepatitis involves confirming both the presence of bilirubin elevation and the underlying hepatitis etiology.

Initial clinical evaluation

• Detailed medical history (risk exposures, vaccination, alcohol use).
• Physical examination focusing on skin, eyes, abdominal organomegaly, and signs of chronic liver disease.

Laboratory tests

• Liver function panel: Elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) often > 5‑10 × upper‑limit in acute hepatitis; bilirubin (total > 2.5 mg/dL indicates jaundice).
• Serologic hepatitis markers:
  • HAV IgM (acute infection).
  • HBsAg, anti‑HBc IgM, HBeAg (acute) and HBsAb, HBcAb (chronic).
  • HCV antibody + HCV RNA PCR (detects active infection).
  • HDV antibody (if HBV positive).
  • HEV IgM/IgG (epidemic areas).
• Autoimmune markers: ANA, SMA, LKM‑1 antibodies.
• Metabolic screens: Ceruloplasmin (Wilson’s), iron studies (hemochromatosis).
• Complete blood count, coagulation profile (PT/INR), albumin level.

Imaging studies

• Abdominal ultrasound: Assess liver size, echotexture, presence of gallstones or biliary obstruction.
• Transient elastography (FibroScan): Non‑invasive measurement of fibrosis.
• CT or MRI: Reserved for ambiguous cases or to evaluate complications (e.g., hepatic masses).

Liver biopsy

Considered when serology is inconclusive, or to stage fibrosis and guide treatment, especially in chronic hepatitis B or C.

Treatment Options

Treatment is two‑pronged: managing the jaundice (symptomatic) and addressing the underlying hepatitis.

Acute viral hepatitis (A, E)

• Supportive care – rest, adequate hydration, and nutrition.
• Antiemetics for nausea, analgesics (avoid acetaminophen > 2 g/day).
• Monitoring of liver enzymes and bilirubin; most recover fully within 2‑8 weeks.

Chronic hepatitis B

• First‑line antivirals: Tenofovir disoproxil fumarate (TDF) or Tenofovir alafenamide (TAF), entecavir.
• Treatment indications: HBV DNA > 2,000 IU/mL with elevated ALT or evidence of fibrosis (≥ F2).
• Goal: Suppress viral replication, reduce inflammation, prevent cirrhosis.

Chronic hepatitis C

• Direct‑acting antiviral (DAA) regimens (e.g., sofosbuvir/ledipasvir, glecaprevir/pibrentasvir) for 8‑12 weeks.
• SVR (sustained virologic response) > 95 % cure rate; resolves jaundice when liver inflammation subsides.

Autoimmune hepatitis

• Induction therapy with corticosteroids (prednisone 30‑60 mg/day) plus azathioprine.
• Maintenance with low‑dose prednisone + azathioprine or mycophenolate.

Alcoholic and drug‑induced hepatitis

• Immediate cessation of alcohol or offending drug.
• Nutrition support (high‑protein, vitamin B complex, thiamine).
• Corticosteroids may be considered in severe alcoholic hepatitis (Maddrey’s Discriminant Function > 32).

Symptomatic management of jaundice

• Phototherapy is rarely needed in adults but can be used in severe hyperbilirubinemia.
• Itch relief: cholestyramine, antihistamines, or rifampin for refractory pruritus.
• Hydration and balanced electrolytes to support renal clearance of conjugated bilirubin.

Lifestyle modifications

• Abstain from alcohol and illicit drugs.
• Maintain a healthy weight (BMI 18‑25) to reduce fatty liver burden.
• Vaccinate against hepatitis A and B if not already immune.
• Adopt a low‑sodium, high‑protein diet if cirrhosis is present.

Living with Jaundice due to Hepatitis

Even after the acute phase, many patients will continue to monitor liver health. Practical daily tips include:

• Medication safety: Use only liver‑friendly drugs; avoid over‑the‑counter acetaminophen > 2 g/day.
• Nutrition: Emphasize fruits, vegetables, whole grains, and lean protein. Limit fried foods, added sugars, and saturated fats.
• Hydration: Aim for 2‑3 L of water daily unless fluid‑restricted for ascites.
• Regular follow‑up: Labs every 3‑6 months (ALT, AST, bilirubin, INR, albumin) and imaging as advised.
• Sun protection: Yellow skin can be more sensitive; use sunscreen SPF 30+.
• Support networks: Join hepatitis support groups (e.g., Hepatitis B Foundation, Hepatitis C Trust) for emotional help and up‑to‑date resources.

Prevention

Preventing jaundice starts with preventing hepatitis infection and protecting liver health.

• Vaccination: Hepatitis A and B vaccines are > 95 % effective. Recommended for all infants, travelers to endemic areas, and high‑risk adults.
• Safe injection practices: Use sterile needles, never share personal grooming tools.
• Sexual health: Condoms reduce HBV/HCV transmission.
• Food & water safety: Avoid raw shellfish and untreated water in regions with HEV or HAV risk.
• Alcohol moderation: No more than 1 drink/day for women, 2 for men; abstinence if liver disease present.
• Medication awareness: Discuss any new prescription or herbal supplement with a healthcare professional.
• Regular screening: One‑time hepatitis C test for adults born 1945‑1965; repeat for those with ongoing risk.

Complications

If left untreated, jaundice signals ongoing liver injury that may progress to serious sequelae:

• Cirrhosis: Irreversible fibrosis leading to portal hypertension, ascites, variceal bleeding.
• Hepatocellular carcinoma (HCC): Chronic HBV and HCV infection increase HCC risk 15‑20‑fold; surveillance with ultrasound + AFP every 6 months is recommended.
• Acute liver failure: Sudden loss of hepatic function, coagulopathy, encephalopathy; mortality > 30 % without transplant.
• Cholestatic pruritus and skin breakdown: Severe itching can lead to secondary infections.
• Renal dysfunction (hepatorenal syndrome): Result of severe portal hypertension.
• Pregnancy complications: Vertical transmission of HBV/HCV; increased risk of pre‑term birth.

When to Seek Emergency Care

---

Sources: 1. World Health Organization. Hepatitis Fact Sheet. 2023. 2. Mayo Clinic. Jaundice. 2024. 3. CDC. Hepatitis B and C Surveillance Data. 2022. 4. NIH – National Institute of Diabetes and Digestive and Kidney Diseases. Hepatitis Overview. 2024. 5. Cleveland Clinic. Autoimmune Hepatitis Treatment Guidelines. 2023.

```